Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
71 hedge funds and large institutions have $206M invested in Lumos Pharma, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 8 closing their positions.
372% more call options, than puts
Call options by funds: $38.8M | Put options by funds: $8.22M
127% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less capital invested
Capital invested by funds: $215M → $206M (-$8.71M)
4% less funds holding
Funds holding: 74 → 71 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.36M |
| 2 |
Barclays
London,
United Kingdom
|
+$2.52M |
| 3 |
First Eagle Investment Management
New York
|
+$2.45M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.77M |
| 5 |
MCM
Montibus Capital Management
Portland,
Oregon
|
+$1.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.3M |
| 2 |
SCM
Sigma Capital Management
Stamford,
Connecticut
|
-$1.48M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$943K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$753K |
| 5 |
CII
CR Intrinsic Investors
Stamford,
Connecticut
|
-$718K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PP
76
PDT Partners
New York
| – | -$359K | -2,024 | Closed |
|
77
Two Sigma Investments
New York
| – | -$273K | -1,542 | Closed |
|
78
Jane Street
New York
| – | -$226K | -1,275 | Closed |
|
|
ST
79
Spot Trading
Chicago,
Illinois
| – | -$179K | -1,112 | Closed |
|
LUMO Hedge Fund Activity: Q3 2013 in Review
71 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q3 2013, worth a combined $206M — down 4.1% from $215M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of LUMO and 5 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 34 added.
The largest buyer was Millennium Management, adding an estimated $5.36M. The largest seller was Fidelity Investments, cutting an estimated $10.3M.
- 71 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q3 2013, down from 74 in Q2 2013.
- Funds reported $206M of Lumos Pharma, Inc. Common Stock stock for Q3 2013, down 4.1% quarter-over-quarter.
- 5 funds opened new Lumos Pharma, Inc. Common Stock positions in Q3 2013 and 8 closed out, a net change of -3 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q3 2013 was Millennium Management, an estimated $5.36M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q3 2013 was Fidelity Investments, an estimated $10.3M sold.
Based on aggregated 13F filings for Q3 2013.